Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Neurologic Injuries in Adults With Urea Cycle Disorders
This study is currently recruiting participants.
Verified by Office of Rare Diseases (ORD), September 2008
Sponsors and Collaborators: Office of Rare Diseases (ORD)
Rare Diseases Clinical Research Network
Information provided by: Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier: NCT00472732
  Purpose

Urea cycle disorders (UCDs) are a group of rare inherited metabolism disorders. The purpose of this study is to evaluate how UCD-related neurologic injuries affect adults with one of the most common types of UCD.


Condition
Brain Diseases, Metabolic, Inborn
Urea Cycle Disorder
Ornithine Transcarbamylase Deficiency

Genetics Home Reference related topics: argininosuccinic aciduria citrullinemia N-acetylglutamate synthase deficiency ornithine transcarbamylase deficiency ornithine translocase deficiency
MedlinePlus related topics: Brain Diseases
Drug Information available for: Ammonia
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Assessing Neural Mechanisms of Injury in Inborn Errors of Urea Metabolism Using Structural MRI, Functional MRI, and Magnetic Resonance Spectroscopy

Further study details as provided by Office of Rare Diseases (ORD):

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 46
Study Start Date: March 2007
Estimated Study Completion Date: July 2009
Estimated Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD
2
Healthy males or females without known medical or metabolic disorder (control group)

Detailed Description:

UCDs are a group of rare genetic diseases that affect how protein is broken down in the body. The cause of UCDs is a deficiency in one of eight enzymes responsible for removing ammonia, a waste product of protein metabolism, from the bloodstream. Normally, ammonia is converted into urea and then removed from the body in the form of urine. However, in people with UCDs, ammonia accumulates unchecked and is not removed from the body. Toxic levels of ammonia can build up and cause irreversible neurologic damage that can affect metabolism, cognition, sensation, and movement. This study will focus on the most common enzyme disorder among UCDs, ornithine transcarbamylase deficiency (OTCD), a disorder inherited from mothers. Using different types of magnetic resonance imaging (MRI), this study will evaluate how UCD-related neurologic injuries affect metabolism, cognition, sensation, and movement in adults with OTCD.

Participants in this study will attend an initial study visit that will include a review of medical history, current symptoms, impairments, and diet history; urine and blood collection; a physical exam; a full neurological exam; and cognitive and motor testing. During this visit, participants will undergo imaging studies and additional cognitive and motor testing over a 2- to 3-day period. This will include standard MRI studies and four sessions consisting of functional MRI (fMRI), diffusion tensor imaging, and 1H magnetic resonance spectroscopy. For the fMRI study, participants perform various motor and behavioral tasks while in the imaging scanner. Magnetic resonance spectroscopy (MRS) is used to study and evaluate the chemical makeup of specific brain areas. Diffusion tensor imaging is used to assess myelination of major brain pathways and their alteration in disease states. This study will involve one-time participation. There will be no follow-up visits for this study.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD

Criteria

Inclusion Criteria for Participants with OTCD:

  • Diagnosis of OTCD or heterozygote state of OTCD by metabolic or molecular means. Female participants must be clinically stable and heterozygous for OTCD. Male participants must be hemizygous for late onset OTCD.

Inclusion Criteria for Healthy Controls:

  • No known medical or metabolic disorder

Inclusion Criteria for All Participants:

  • IQ of at least 80
  • Willing to travel to study site
  • English-speaking
  • Age between 18 and 60 years

Exclusion Criteria for All Participants:

  • Currently being treated for an acute illness
  • History of neuropsychiatric drug use
  • Unable to undergo MRI scanning without being sedated
  • Unable to participate in neurocognitive and/or motor testing
  • Metal device in body that might interfere with MRI scanning
  • Pregnancy or breastfeeding
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00472732

Contacts
Contact: Kyle Shattuck 202-687-3592

Locations
United States, District of Columbia
George Washington University School of Medicine Not yet recruiting
Washington, District of Columbia, United States, 20037
Principal Investigator: Mark Batshaw, MD            
Principal Investigator: Mendel Tuchman, MD            
Georgetown University Recruiting
Washington, District of Columbia, United States, 20057
Principal Investigator: Stanley Fricke, PhD            
Principal Investigator: John Van Meter, PhD            
Principal Investigator: Andrea Gropman, MD            
Sponsors and Collaborators
Rare Diseases Clinical Research Network
Investigators
Study Chair: Andrea Groopman, MD Childrens Research Institute
  More Information

Publications:
Responsible Party: Children's National Medical Center ( Andrea Groopman, MD )
Study ID Numbers: RDCRN 5104
Study First Received: May 11, 2007
Last Updated: September 2, 2008
ClinicalTrials.gov Identifier: NCT00472732  
Health Authority: United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):
UCD
OTCD
Ammonia
Urea Metabolism
Inborn Errors

Study placed in the following topic categories:
Metabolic Diseases
Urea cycle disorders
Amino Acid Metabolism, Inborn Errors
Central Nervous System Diseases
Brain Diseases
Ornithine Carbamoyltransferase Deficiency Disease
Metabolism, Inborn Errors
Inborn amino acid metabolism disorder
Genetic Diseases, Inborn
Brain Diseases, Metabolic, Inborn
Metabolic disorder
Ornithine Transcarbamylase Deficiency
Brain Diseases, Metabolic
Deficiency Diseases

Additional relevant MeSH terms:
Pathologic Processes
Disease
Nervous System Diseases

ClinicalTrials.gov processed this record on January 14, 2009